{"id":87507,"date":"2026-10-14T14:42:00","date_gmt":"2026-10-14T14:42:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=87507"},"modified":"2026-10-15T01:49:35","modified_gmt":"2026-10-15T01:49:35","slug":"liquid-biopsy-market-research-to-reach-usd-27-42-billion-by-2035-as-cancer-blood-tests-ai-diagnostics-and-precision-oncology-advance","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/liquid-biopsy-market-research-to-reach-usd-27-42-billion-by-2035-as-cancer-blood-tests-ai-diagnostics-and-precision-oncology-advance\/","title":{"rendered":"Liquid Biopsy Market Research to Reach USD 27.42 Billion by 2035 as Cancer Blood Tests, AI Diagnostics and Precision Oncology Advance"},"content":{"rendered":"

Latest Market Data and Industry News: Guardant Health Expands Companion Diagnostics, While Grail’s Galleri Moves Closer to a Potential FDA Decision by Towards Healthcare, a sister firm of Precedence Research<\/em><\/p>\n

Ottawa, Oct. 14, 2026 (GLOBE NEWSWIRE) — The global liquid biopsy market is projected to grow from USD 7.08 billion in 2025<\/a> to USD 27.42 billion by 2035, expanding at a compound annual growth rate (CAGR) of 14.5% from 2026 to 2035. At the same time, new regulatory developments, advances in circulating tumor DNA analysis, and growing pharmaceutical partnerships are reshaping the competitive landscape<\/a> for cancer diagnostics. Towards Healthcare’s market research identifies North America as the leading region and Asia Pacific as the fastest-growing market with next-generation sequencing<\/a>, circulating nucleic acids, and therapy selection among the sector’s major areas of activity.<\/p>\n

<\/p>\n

Download a sample: Liquid Biopsy Market Report Sample<\/a> to review the report’s coverage and research scope.<\/p>\n

Market Data Snapshot<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n
Market Indicator<\/b><\/td>\nData<\/b><\/td>\nBusiness Implication<\/b><\/td>\n<\/tr>\n
Global market size, 2025<\/td>\nUSD 7.08 billion<\/td>\nEstablished commercial base for molecular diagnostics and precision oncology<\/td>\n<\/tr>\n
Projected market size, 2035<\/td>\nUSD 27.42 billion<\/td>\nExpanding opportunity for diagnostic developers, laboratories, and technology suppliers<\/td>\n<\/tr>\n
Forecast CAGR, 2026\u20132035<\/td>\n14.5<\/td>\n%<\/td>\nSupports long-term investment in platforms, assays, and commercialization<\/td>\n<\/tr>\n
U.S. market size, 2026<\/td>\nUSD 2.78 billion<\/td>\nImportant near-term market for regulatory, clinical, and commercial strategies<\/td>\n<\/tr>\n
U.S. market forecast, 2035<\/td>\nUSD 8.90 billion<\/td>\nSignificant opportunity for testing companies and companion diagnostic providers<\/td>\n<\/tr>\n
North America, 2025<\/td>\n46% of global market<\/td>\nLargest regional base for commercial deployment<\/td>\n<\/tr>\n
Middle East market, 2025<\/td>\nUSD 212.4 million<\/td>\nEmerging opportunity for access, distribution, and diagnostic infrastructure<\/td>\n<\/tr>\n
Middle East forecast, 2035<\/td>\nUSD 874.34 million<\/td>\nLong-term potential for regional market development<\/td>\n<\/tr>\n<\/table>\n

Market estimates and forecasts: Towards Healthcare’s Liquid Biopsy Market report, updated September 10, 2026. Regional and country estimates should be interpreted within the report’s stated market definitions.<\/p>\n

What the Latest Market Data Shows<\/b><\/p>\n

Liquid biopsy is moving beyond a niche alternative to tissue biopsy. The technology analyzes biomarkers including circulating tumor DNA<\/a> (ctDNA), circulating tumor cells, RNA, and other molecular signals from blood and selected other body fluids. Its commercial value lies in enabling molecular profiling, therapy selection, treatment monitoring, and detection of residual or recurring disease without requiring a conventional tissue sample in every case.<\/p>\n

The market’s projected expansion reflects several overlapping demand pools: precision oncology<\/a>, targeted cancer therapies, molecular monitoring, and the development of blood-based screening tests. These applications have different evidence requirements and commercial pathways, meaning companies need to assess them separately rather than treating all liquid biopsy products as interchangeable.<\/p>\n

The U.S. liquid biopsy market<\/a> alone is projected to increase from USD 2.78 billion in 2026 to USD 8.90 billion by 2035, at a CAGR of 13.82%. That outlook makes regulatory authorization, reimbursement, clinical utility, and relationships with pharmaceutical developers important competitive factors for diagnostic businesses.<\/p>\n

Schedule a meeting: Connect with our expert team<\/a> to discuss your requirements.<\/p>\n

Segment trends and their commercial implications<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n
Segment<\/b><\/td>\nMarket Position or Trend<\/b><\/td>\nWhat It Means for Decision-Makers<\/b><\/td>\n<\/tr>\n
Next-generation sequencing (NGS)<\/td>\nDominant technology segment<\/td>\nSupports comprehensive genomic profiling and complex biomarker analysis<\/td>\n<\/tr>\n
Circulating nucleic acids<\/td>\nLeading biomarker category<\/td>\nMaintains the importance of sensitive ctDNA and related nucleic-acid assays<\/td>\n<\/tr>\n
Cancer applications<\/td>\nLargest application category<\/td>\nKeeps oncology the core commercial market<\/td>\n<\/tr>\n
Therapy selection<\/td>\nLeading clinical application<\/td>\nCreates opportunities linked to targeted drug development and companion diagnostics<\/td>\n<\/tr>\n
Early screening<\/td>\nExpected to expand rapidly<\/td>\nOpens a potential growth market, but requires careful evaluation of clinical utility and regulatory evidence<\/td>\n<\/tr>\n
Exosomes and microvesicles<\/td>\nProjected high-growth biomarker category<\/td>\nEncourages research into additional molecular signals and differentiated assay designs<\/td>\n<\/tr>\n
Kits and reagents<\/td>\nExpected to grow rapidly<\/td>\nCreates recurring-revenue opportunities alongside instrument sales<\/td>\n<\/tr>\n
Specialty clinics<\/td>\nProjected high-growth end-user category<\/td>\nIncreases the importance of access, workflow integration, and test availability<\/td>\n<\/tr>\n<\/table>\n

Segment positions and outlooks are based on Towards Healthcare’s published market analysis.<\/p>\n

The key strategic distinction is between tests used to guide treatment in patients with known cancer and tests intended to screen apparently healthy populations. Therapy-selection assays can be tied to specific treatment decisions and companion diagnostic pathways. Multi-cancer early-detection tests, by contrast, must demonstrate how their results should guide follow-up, how false positives and false negatives are managed, and whether screening improves meaningful health outcomes.<\/p>\n

For manufacturers and investors, this distinction affects clinical-development priorities, product positioning, pricing assumptions, reimbursement planning, and the evidence required before scaling commercial deployment.<\/p>\n

Latest Liquid Biopsy Industry News and Company Developments<\/b><\/p>\n

The strongest competitive signals in 2026 are coming from companion diagnostics<\/a>, minimal residual disease (MRD) testing, multi-cancer early detection, and expanding reimbursement. These developments show how commercial success increasingly depends on evidence, regulatory status, and access not just the ability to identify cancer-associated biomarkers.<\/p>\n

1. Guardant Health expands companion diagnostic capabilities<\/b><\/p>\n

On October 8, 2026, Guardant Health announced European approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant in advanced estrogen receptor-positive breast cancer. The development strengthens the connection between liquid biopsy testing and targeted treatment decisions.<\/p>\n

In May 2026, the U.S. FDA also approved an expanded version of Guardant360 Liquid CDx, integrating genomic and epigenomic insights<\/a> and assessing a genomic footprint 100 times wider than the previously approved version. The expansion illustrates the competitive value of broader molecular profiling and the potential to support additional treatment decisions.<\/p>\n

For pharmaceutical companies, this creates opportunities to evaluate companion diagnostic partnerships earlier in drug development<\/a>. For diagnostic developers, it increases the importance of assay validation, biomarker coverage, regulatory submissions, and integration into oncology treatment pathways<\/a>.<\/p>\n

2. Grail’s Galleri advances toward a potential regulatory milestone<\/b><\/p>\n

In September 2026, an FDA advisory panel voted 7\u20132 that the potential benefits of Grail’s Galleri multi-cancer early-detection blood test outweighed its risks. The test is designed to identify signals associated with more than 50 cancer types from a blood sample.<\/p>\n

However, the advisory decision is not an FDA marketing approval. Questions remain about sensitivity, false-positive results, detection of early-stage cancers, follow-up procedures, and evidence of improved patient outcomes. The distinction is commercially important: a favorable advisory vote can improve a product’s regulatory outlook without guaranteeing approval, reimbursement, or widespread adoption.<\/p>\n

Companies developing multi-cancer early-detection tests should therefore track clinical performance, confirmatory testing pathways, healthcare-provider acceptance, regulatory milestones, and payer decisions together.<\/p>\n

3. MRD testing gains further access and clinical momentum<\/b><\/p>\n

Quest Diagnostics announced in June 2026 that its Haystack MRD circulating tumor DNA test had received New York State approval, broadening access to testing for residual or recurring disease in solid-tumor cancers. The company stated that the test was then authorized for patient testing in all 50 U.S. states.<\/p>\n

Meanwhile, Natera’s Signatera received Japanese regulatory approval for adjuvant colorectal cancer applications in 2026, and expanded guideline recognition has supported interest in ctDNA-based MRD testing across selected cancer settings.<\/p>\n

These developments make MRD testing a strategically important area for monitoring cancer recurrence and treatment response. They also highlight the need to distinguish regulatory clearance, clinical guideline inclusion, reimbursement coverage, and demonstrated clinical utility four different factors that affect market adoption.<\/p>\n

Explore further insights: Visit the Liquid Biopsy Market report<\/a> for market forecasts, segment analysis, regional intelligence, and company coverage.<\/p>\n

Company intelligence snapshot<\/b><\/p>\n\n\n\n\n\n\n\n
Company<\/b><\/td>\nRecent Development<\/b><\/td>\nStrategic Significance<\/b><\/td>\n<\/tr>\n
Guardant Health<\/td>\nExpanded Guardant360 Liquid CDx authorization and European companion diagnostic approval<\/td>\nStrengthens precision-oncology positioning and pharmaceutical partnerships<\/td>\n<\/tr>\n
Grail<\/td>\nGalleri received a favorable FDA advisory panel vote in September 2026<\/td>\nCreates a potential pathway toward broader multi-cancer screening, subject to further regulatory decisions<\/td>\n<\/tr>\n
Quest Diagnostics<\/td>\nHaystack MRD received New York State approval in June 2026<\/td>\nBroadens access to ctDNA-based residual disease testing<\/td>\n<\/tr>\n
Natera<\/td>\nSignatera received Japanese approval for adjuvant colorectal cancer applications<\/td>\nSupports international expansion of MRD testing<\/td>\n<\/tr>\n
Freenome<\/td>\nSimpleScreen Lung received FDA Breakthrough Device Designation in 2026<\/td>\nAdvances development of a blood-based lung cancer screening test<\/td>\n<\/tr>\n<\/table>\n

The competitive implication is clear: liquid biopsy providers are pursuing distinct commercial strategies. Some are focusing on treatment selection and companion diagnostics; others are building MRD monitoring portfolios or pursuing multi-cancer screening. Investors and business-development teams need to benchmark these strategies separately.<\/p>\n

Where the Next Market Opportunities Are Emerging<\/b><\/p>\n

Companion diagnostics and precision oncology<\/b><\/p>\n

Liquid biopsy can help identify molecular alterations relevant to targeted therapies<\/a> when tissue testing is unavailable, insufficient, or difficult to obtain. Pharmaceutical companies can use these capabilities to support clinical trial enrollment, biomarker stratification, and companion diagnostic development.<\/p>\n

The opportunity for diagnostic businesses is to establish partnerships around specific drug-development programs and cancer indications rather than relying exclusively on broad testing portfolios.<\/p>\n

Multi-cancer early detection<\/b><\/p>\n

Blood-based screening tests could expand the addressable population beyond patients already diagnosed with cancer. However, commercial opportunity depends on demonstrating clinical value, managing false-positive and false-negative results, establishing confirmatory diagnostic pathways, and securing payer coverage.<\/p>\n

Businesses should evaluate these requirements before using potential screening populations to build revenue forecasts.<\/p>\n

Asia Pacific expansion<\/b><\/p>\n

Asia Pacific is projected to be the fastest-growing regional market. China, Japan, India, South Korea, and Australia offer different combinations of healthcare infrastructure, oncology research, diagnostic capabilities, reimbursement environments, and patient access.<\/p>\n

Companies considering regional expansion should compare country-level demand, laboratory capabilities, regulatory requirements, distribution networks, local partnerships, and test affordability before committing resources.<\/p>\n

AI-enabled molecular analysis<\/b><\/p>\n

AI and computational biology can support biomarker identification<\/a>, signal interpretation, and analysis of complex molecular datasets. Their commercial contribution depends on analytical validation, reproducibility, integration into laboratory workflows, and evidence that improved interpretation translates into meaningful clinical utility.<\/p>\n

Reagents, laboratory services, and manufacturing<\/b><\/p>\n

The projected growth of kits and reagents creates opportunities for recurring revenue, while increased testing volumes can support laboratory automation, sample-processing technologies, sequencing workflows, and specialized diagnostic services.<\/p>\n

Suppliers should monitor instrument compatibility, reagent demand, production scalability, quality requirements, and laboratory purchasing criteria.<\/p>\n

Risks and Challenges Companies Should Monitor<\/b><\/p>\n

The market’s growth potential does not eliminate commercial and clinical uncertainty. Key issues include:<\/p>\n